These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10667120)

  • 1. [Latanoprost (Xalatan) and a systemic respiratory effect? Apropos of a case].
    Veyrac G; Chiffoleau A; Cellerin L; Larousse C; Bourin M
    Therapie; 1999; 54(4):494-6. PubMed ID: 10667120
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic side effects of topical latanoprost.
    Rajan MS; Syam P; Liu C
    Eye (Lond); 2003 Apr; 17(3):442-4. PubMed ID: 12724721
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma.
    Maruyama K; Shirato S; Haneda M
    Jpn J Ophthalmol; 2005; 49(1):61-2. PubMed ID: 15692779
    [No Abstract]   [Full Text] [Related]  

  • 4. Latanoprost and periocular skin color changes.
    Wand M; Ritch R; Isbey EK; Zimmerman TJ
    Arch Ophthalmol; 2001 Apr; 119(4):614-5. PubMed ID: 11296032
    [No Abstract]   [Full Text] [Related]  

  • 5. Allergic contact dermatitis caused by topical eye drops.
    Spaeth GL
    Am J Ophthalmol; 2006 Oct; 142(4):706. PubMed ID: 17011880
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
    Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
    Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Occurrence of bronchial obstruction in asthma patients immediately following administration of timolol-containing eyedrops].
    John KD; Kloss G; Lübcke P
    Prax Klin Pneumol; 1985 Aug; 39(8):281-3. PubMed ID: 4034491
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe hypotony following cataract extraction in a patient on latanoprost.
    Wu G; Morrell A
    Eye (Lond); 2000 Dec; 14(Pt 6):915-6. PubMed ID: 11584861
    [No Abstract]   [Full Text] [Related]  

  • 11. Bilateral poliosis and granulomatous anterior uveitis associated with latanoprost use and apparent hypotrichosis on its withdrawal.
    Waheed K; Laganowski H
    Eye (Lond); 2001 Jun; 15(Pt 3):347-9. PubMed ID: 11450742
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma.
    Ekatomatis P
    Br J Ophthalmol; 2001 Aug; 85(8):1008-9. PubMed ID: 11501520
    [No Abstract]   [Full Text] [Related]  

  • 14. Contact dermatitis caused by latanoprost-containing eye drops with good tolerance to bimatoprost eye drops.
    Pérez-Rodríguez E; González-Pérez R; Poza P; Feliciano L; López-Correcher B; Matheu V
    Contact Dermatitis; 2008 Jun; 58(6):370-1. PubMed ID: 18503690
    [No Abstract]   [Full Text] [Related]  

  • 15. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops.
    Flórez A; Rosón E; Conde A; González B; García-Doval I; de la Torre C; Cruces M
    J Am Acad Dermatol; 2005 Nov; 53(5):909-11. PubMed ID: 16243161
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
    Chou SY; Chou CK; Kuang TM; Hsu WM
    Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
    Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
    J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K; Shirato S
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart block following topical latanoprost treatment.
    De Smit E; Theodorou M; Hildebrand GD; Bloom P
    BMJ Case Rep; 2011 Oct; 2011():. PubMed ID: 22679164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma.
    Nakamura Y; Nakamura Y; Morine-Shinjo S; Sakai H; Sawaguchi S
    Acta Ophthalmol Scand; 2004 Apr; 82(2):158-60. PubMed ID: 15043533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.